Moteur de recherche d’entreprises européennes
Financement de l’UE (1 467 400 €) : Modèles cellulaires 3D in vitro de tissus osseux sains et vieillissants ostéopathologiques pour l’implantation et l’essai de médicaments dans le cadre d’un réseau … Hor01/01/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Modèles cellulaires 3D in vitro de tissus osseux sains et vieillissants ostéopathologiques pour l’implantation et l’essai de médicaments dans le cadre d’un réseau multidisciplinaire
OSTEONET aims to (i) build a multidisciplinary research network involving experts of technical and medical disciplines to merge their expertise and exploit possible synergies for the development of reliable and sustainable 3D in vitro cell models of healthy and aged bone tissue and (ii) train a cohort of scientists and technologists in exploiting the model features to increase knowledge on the effects of ageing on bone biology and mechanobiology, and on bone response to drugs, to leverage the use of 3D cell models in clinics and basic/industrial research labs. Bone ageing reduces the quality of life of the elderly and puts social and economic burden on society. Ageing bones fail more easily when challenged mechanically or with toxicants or pollutants, and respond differently to drugs than healthy bone. To personalize therapies and enable better preventive care for the elderly it is essential to develop reliable and sustainable in vitro models of aged bone tissue alternative to animal tests which often fail to capture human-specific features. Several scientific studies support the idea that in vitro models of bone tissue are an outstanding resource for (i) the comprehension of bone physiology, (ii) a better understanding of pathological pathways in most bone dysfunctions, (iii) testing new or repurposed drugs for bone treatment before preclinical trials with animal models. The networking activities planned in OSTEONET will unravel and share knowledge on the mechanisms driving the information transfer from the biochemical and biomechanical levels, which drive osteosynthesis and osseointegration, to the cascade of molecular and cellular events emerging as an elaborated and physiological bone, and on the mechanisms of the different response of healthy and aged bone tissue to mechano-biological stimuli and drugs.
| 7HC Srl | 138 000 € |
| Aifactory SP Zoo | 110 400 € |
| Athina-Erevnitiko Kentro Kainotomias Stis Technologies TIS Pliroforias, TON Epikoinonion Kai TIS Gnosis | 138 000 € |
| Cellex Srl | 363 400 € |
| Consorzio Di Ricerca Hypatia | 82 800 € |
| Ctadventure sp. z o.o. | 0,00 € |
| Efiis Sistemiki Viologia Monoprosopi ΙΚΕ | 110 400 € |
| Elvesys | 0,00 € |
| Lithoz GmbH | 0,00 € |
| Medizinische Universitaet Wien | 50 600 € |
| Microfluidics Innovation Center | 4 600,00 € |
| TECHNISCHE HOCHSCHULE MITTELHESSEN | 110 400 € |
| TEL AVIV UNIVERSITY | 69 000 € |
| Universita Della Calabria | 193 200 € |
| Universiteit Gent | 55 200 € |
| Universitetet I Bergen | 41 400 € |
https://cordis.europa.eu/project/id/101086329
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.